Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Ledipasvir / Sofosbuvir (Harvoni & authorized generic by Year
Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — U.S. sales ($M) ($M)
Gilead Sciences Ledipasvir / Sofosbuvir (Harvoni & authorized generic: $39M in FY2023, down 15.2% from a year earlier. That is the lowest of the 8 years on record here. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
Source: Form 10-K (filed 2024-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | 39 | -15.2% | Form 10-K (filed 2024-02-23) ↗ |
| FY2022 | Dec 31, 2022 | 46 | -45.2% | Form 10-K (filed 2024-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 84 | -8.7% | Form 10-K (filed 2024-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 92 | -70.5% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 312 | -61.1% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 802 | -73.7% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 3,053 | -38.2% | Form 10-K (filed 2019-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 4,941 | – | Form 10-K (filed 2019-02-26) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Ledipasvir / Sofosbuvir (Harvoni & authorized generic ($M), annual FY2016–FY2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-harvoni-us
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.